Previous Article | Next Article 
Journal of Clinical Microbiology, April 2007, p. 1336-1338, Vol. 45, No. 4
0095-1137/07/$08.00+0 doi:10.1128/JCM.02108-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Determination of bft Gene Subtypes in Bacteroides fragilis Clinical Isolates
Mario J. Avila-Campos,1
Chengxu Liu,2
Yuli Song,2
Marie-Claire Rowlinson,2 and
Sydney M. Finegold2,3,4,5*
Anaerobe Laboratory, Department of Microbiology, ICB, University of Sao Paulo, Sao Paulo SP, Brazil,1
Wadsworth Anaerobe Laboratory,2
Infectious Diseases Section,3
VA Medical Center, West Los Angeles, and Department of Medicine,4
Department of Microbiology, Immunology, and Molecular Genetics, UCLA School of Medicine, Los Angeles, California5
Received 13 October 2006/
Returned for modification 5 January 2007/
Accepted 4 February 2007

ABSTRACT
A rapid multiplex PCR approach was developed to detect the
bft gene subtypes in
Bacteroides fragilis clinical isolates. This
technique could be used to look at the epidemiology of enterotoxigenic
strains of
B. fragilis in clinical infections and whether there
is a correlation between disease and the presence of
B. fragilis enterotoxin.

TEXT
Bacteroides fragilis is the most commonly isolated anaerobe
from human clinical infections and is considered to be the most
virulent species in the
B. fragilis group (
6,
12). An association
between enterotoxigenic strains of
B. fragilis (ETBF) and diarrheal
disease was first noted in livestock and was subsequently reported
in human diarrheal disease in 1987 by Myers et al. (
7-
9). There
is now growing evidence worldwide indicating that ETBF strains
are associated with human diarrheal disease, with the majority
of the studies conducted with young children (
1,
10,
11). In
addition, a study by Kato et al. implicated ETBF in approximately
30% of the bloodstream infections caused by
B. fragilis (
3).
There are also several studies that have investigated the epidemiology
and genotypic diversity of ETBF in human specimens (
2,
3,
5).
ETBF strains have been found to produce a 20-kDa zinc metalloprotease
toxin, BFT (
B. fragilis toxin), of which there are three distinct
subtypes (
14). In this study, a multiplex PCR was developed
to investigate the presence of the three subtypes of
B. fragilis enterotoxin (
bft) gene in
B. fragilis human clinical strains.
Three hundred twenty-nine B. fragilis strains were isolated from various clinical specimens (Table 1). All of these isolates originated from human clinical specimens and were identified and stored at the Wadsworth Anaerobe Laboratory, VA Medical Center, West Los Angeles, CA. B. fragilis VPI 13784 (produces BFT subtype 1), 86-5443-2-2 (produces BFT subtype 2), and Korea 419 (produces BFT subtype 3) were used as reference strains and were kindly donated by C. L. Sears of the Johns Hopkins University School of Medicine, Baltimore, MD. A nontoxigenic strain of B. fragilis, ATCC 25285, was used as a negative control. B. fragilis isolates were grown on brucella blood agar under anaerobic conditions at 37°C for 48 h.
The
bft gene sequences of
B. fragilis species retrieved from
GenBank were analyzed by multisequence alignment with CLUSTAL-W
(
http://genome.kribb.re.kr). On the basis of the multisequence
alignment analysis data, two reverse primers were newly designed
(BFET-TYPE1, 5'-ATT GAA CCA GGA CAT CCC T-3' [specific for
bft-
1];
BFET-TYPE3, 5'-CGT GTG CCA TAA CCC CA-3' [specific for
bft-
3]).
A common forward primer, GBF-201 (5'-GAA CCT AAA ACG GTA TAT
GT-3'), and a reverse primer, GBF-322 (specific for
bft-
2; 5'-CGC
TCG GGC AAC TAT-3'), previously designed by Kato et al., were
also used (
4). The primer sequences were analyzed with the NetPrimer
analysis software (
http://www.premierbiosoft.com/netprimer).
The specificities of these primers were predicted by comparison
to all available sequences by using the BLAST database search
program (
www.ncbi.nlm.nih.gov/BLAST) and were further tested
by running PCR with DNA samples from 10 type strains of
B. fragilis group species and 3 reference strains representing three subtypes
of ETBF. To prepare a DNA sample for PCR amplification, a bacterial
colony was taken from blood agar culture and resuspended in
200 µl of distilled water in a microcentrifuge tube. The
sample was then boiled for 10 min and centrifuged for 1 min
at 14,000 rpm, and 2 µl of supernatant was used for subsequent
PCR amplification. PCR amplifications were performed in a 30-µl
reaction mixture containing 1
x buffer; 2.0 mM MgCl
2; 200 mM
deoxynucleoside triphosphate; 20 pmol each of GBF-201, BFET-TYPE1,
GBF-322, and BFET-TYPE3; 0.5 U of
Taq DNA polymerase (Promega);
and 2 µl of bacterial sample DNA. Conditions were optimized
as follows: 5 min at 94°C; 3 min at 94°C, 1 min at 63°C,
and 1 min at 72°C for 34 cycles; and 5 min at 72°C.
Gel electrophoresis was performed for 45 min at 125 V on a 6%
acrylamide gel, with visualization by ethidium bromide staining.
The developed multiplex PCR was able to detect the bft gene and distinguish among the three different subtypes. An amplification signal was detected from the three reference ETBF strains, which each carry a specific bft gene subtype but not from other reference strains tested (data not shown), showing that the PCR could specifically detect each bft subtype. An acrylamide gel showing the bands of amplified bft genes is shown in Fig. 1. The numbers and relative frequencies (expressed as percentages) of B. fragilis strains positive for the bft gene isolated from various clinical specimen types are shown in Table 1. The bft-1 subtype was the most prevalent (9%), followed by the bft-2 subtype (3%) and the bft-3 subtype (1%). Of the abscess isolates, 14 (18%) of 76 were found to have the bft gene, although this was found not to be statistically significantly different compared to nonabscess isolates. There were 49 blood isolates in this data set, and only 4 (8%) were found to have the bft gene. In total, the bft gene was found in 13% of the B. fragilis isolates from our clinical specimens.
There are various conflicting reports about ETBF and human clinical
disease. Some studies have shown that ETBF is present in the
normal colonic flora of humans, as well as in clinical infections
(
1,
10). Other studies have found a significant number of ETBF
isolates among certain
B. fragilis clinical isolates, suggesting
their importance as a virulence factor in these infections.
For example, Kato et al. found that 28.1% of the
B. fragilis blood isolates that they tested were ETBF and this was statistically
significantly different compared to nonblood isolates (of which
13.7% were ETBF) (
3). They also found that
bft-
1 was the predominant
subtype. Our study found
bft-
1 to be the predominant subtype,
but unlike Kato et al., we did not find a significantly high
number of blood isolates with the
bft gene. Our study also found
three isolates with the
bft-
3 gene, whereas other studies have
found no
bft-
3 subtypes at all (
13). These differences may be
attributed not only to the types of clinical specimens studied
but also to patient demographics (studies have been conducted
in various countries with different geographical and social
populations) and even sample size. Further studies are needed
to understand why there is diversity in the presence of the
bft subtypes and the possible significance of ETBF in clinical
infections (
12). The multiplex PCR approach that we describe
provides a convenient, dependable, and rapid method for these
studies, which require enough patients in the various clinical
categories to determine statistically significant differences
and to better understand the epidemiology of
B. fragilis diarrheal
disease and its relationship to
bft as a virulence factor.

ACKNOWLEDGMENTS
During the course of this work, M.J.A.-C. was supported by a
fellowship from FAPESP (05/53910-8).

FOOTNOTES
* Corresponding author. Mailing address: Infectious Diseases Section (111F), VA Medical Center, West Los Angeles, CA 90073. Phone: (310) 268-3678. Fax: (310) 268-4458. E-mail:
sidfinegol{at}aol.com 
Published ahead of print on 14 February 2007. 

REFERENCES
1 - Bressane, M. A., L. E. Durigon, and M. J. Avila-Campos. 2001. Prevalence of the Bacteroides fragilis group and enterotoxigenic Bacteroides fragilis in immunodeficient children. Anaerobe 7:277-281.
2 - Claros, M. C., Z. C. Claros, Y. J. Tang, S. H. Cohen, J. Silva, Jr., E. J. Goldstein, and A. C. Rodloff. 2000. Occurrence of Bacteroides fragilis enterotoxin gene-carrying strains in Germany and the United States. J. Clin. Microbiol. 38:1996-1997.[Abstract/Free Full Text]
3 - Kato, N., H. Kato, K. Watanabe, and K. Ueno. 1996. Association of enterotoxigenic Bacteroides fragilis with bacteremia. Clin. Infect. Dis. 23:S83-S86.
4 - Kato, N., C. X., Liu, H. Kato, K. Watanabe, Y. Tanaka, T. Yamamoto, K. Suzuki, and K. Ueno. 2000. A new subtype of the metalloprotease toxin gene and the incidence of the three bft subtypes among Bacteroides fragilis isolates in Japan. FEMS Microbiol. Lett. 182:171-176.[CrossRef][Medline]
5 - Luczak, M., P. Obuch-Woszczatynski, H. Pituch, P. Leszczynski, G. Martirosian, S. Patrick, I. Poxton, R. G. F. Wintermans, L. Dubreuil, and F. Meisel-Mikolajczyk. 2001. Search for enterotoxin gene in Bacteroides fragilis strains isolated from clinical specimens in Poland, Great Britain, The Netherlands and France. Med. Sci. Monit. 7:222-225.[Medline]
6 - Moore, W. E. C., E. P. Cato, and L. V. Holdeman. 1978. Some current concepts in intestinal bacteriology. Am. J. Clin. Nutr. 31:S33-S42.[Abstract]
7 - Myers, L. L., B. D. Firehammer, D. S. Shoop, and M. M. Border. 1984. Bacteroides fragilis: a possible cause of acute diarrheal disease in newborn lambs. Infect. Immun. 44:241-244.[Abstract/Free Full Text]
8 - Myers, L. L., and D. S. Shoop. 1987. Association of enterotoxigenic Bacteroides fragilis with diarrheal disease in young pigs. Am. J. Vet. Res. 48:774-775.[Medline]
9 - Myers, L. L., D. S. Shoop, L. L. Stackhouse, F. S. Newman, R. J. Flaherty, G. W. Letson, and R. B. Sack. 1987. Isolation of enterotoxigenic Bacteroides fragilis from humans with diarrhea. J. Clin. Microbiol. 25:2330-2333.[Abstract/Free Full Text]
10 - Pantosti, A., M. G. Menozzi, A. Frate, L. Sanfilippo, F. D'Ambrosio, and M. Malpeli. 1997. Detection of enterotoxigenic Bacteroides fragilis and its toxin in stool samples from adults and children in Italy. Clin. Infect. Dis. 24:12-16.[Medline]
11 - Sack, R. B., M. J. Albert, K. Allam, P. K. B. Neogi, and M. S Akbar. 1994. Isolation of enterotoxigenic Bacteroides fragilis from Bangladeshi children with diarrhea: a controlled study. J. Clin. Microbiol. 32:960-963.[Abstract/Free Full Text]
12 - Scotto d'Abusco, A. S., M. Del Grosso, and M. Pantosti. 1998. Characterization of the enterotoxin gene of Bacteroides fragilis strains from different human sources, abstr. 3.106, p. 56. In Abstracts of the 2nd World Congress on Anaerobic Bacteria and Infections, 1998. International Society of Anaerobic Bacteria, Boston, MA.
13 - Ulger Toprak, N., D. Rajendram, A. Yagci, S. Gharbia, H. N. Shah, B. M. Gulluoglu, L. M. Akin, P. Demirkalem, T. Celenk, and G. Soyletir. 2006. The distribution of the bft alleles among enterotoxigenic Bacteroides fragilis strains from stool specimens and extraintestinal sites. Anaerobe 12:71-74.[CrossRef][Medline]
14 - Wu, S., L. A. Dreyfus, A. O. Tzianabos, C. Hayashi, and C. L. Sears. 2002. Diversity of the metalloprotease toxin produced by enterotoxigenic Bacteroides fragilis. Infect. Immun. 70:2463-2471.[Abstract/Free Full Text]
Journal of Clinical Microbiology, April 2007, p. 1336-1338, Vol. 45, No. 4
0095-1137/07/$08.00+0 doi:10.1128/JCM.02108-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Sears, C. L.
(2009). Enterotoxigenic Bacteroides fragilis: a Rogue among Symbiotes. Clin. Microbiol. Rev.
22: 349-369
[Abstract]
[Full Text]